StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note published on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Trading Up 9.2 %

Aptevo Therapeutics stock opened at $0.34 on Friday. The business’s 50 day simple moving average is $0.22 and its 200 day simple moving average is $0.40. Aptevo Therapeutics has a 12 month low of $0.14 and a 12 month high of $10.80.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.